Drugs / IONIS GHR-LRx
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03967249 | Jul 2019 → Mar 2022 | acromegaly | Ionis Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT03548415 | Sep 2018 → Feb 2021 | acromegaly | Ionis Pharmaceuticals, Inc. | Completed | Missed primary |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IONIS GHR-LRx | “A Double-Blind, Placebo-Controlled, Phase 2 Study to Assess the Safety, Tolerability, and Efficacy of ISIS 766720 (IONIS-GHR-LRx, an Antisense Inhibitor of the Growth Hormone Receptor)” NCT03548415 ↗ |
| Known as | ISIS 766720 | “A Double-Blind, Placebo-Controlled, Phase 2 Study to Assess the Safety, Tolerability, and Efficacy of ISIS 766720 (IONIS-GHR-LRx, an Antisense Inhibitor of the Growth Hormone Receptor)” NCT03548415 ↗ |
| Action | Inhibit | “an Antisense Inhibitor of the Growth Hormone Receptor” NCT03548415 ↗ |
| Modality | Antisense oligonucleotide | “an Antisense Inhibitor” NCT03548415 ↗ |
| Route | Subcutaneous | “IONIS GHR-LRx administered subcutaneously.” NCT03548415 ↗ |
| Target | GHR | “an Antisense Inhibitor of the Growth Hormone Receptor” NCT03548415 ↗ |